Knight Therapeutics
Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.
Top Stages
6 past transactions
Paladin Pharma
Acquisition in 2025
Paladin Pharma is a pharmaceutical innovation firm that specializes in generic and specialty manufactured medicines. The company focuses on acquiring, licensing, and commercializing emerging pharmaceuticals for the Canadian market. As an operating company of Endo, Inc., Paladin Pharma delivers quality medicines to patients through excellence in development, manufacturing, and commercialization. Their product portfolio includes treatments for various therapeutic areas, addressing unmet medical needs and enhancing patient care.
Grupo Biotoscana
Acquisition in 2019
Grupo Biotoscana is a biopharmaceutical company based in Latin America, formed through the merger of two established specialty pharmaceutical firms with over 25 years of experience each. The company focuses on developing, manufacturing, and selling pharmaceutical products aimed at addressing unmet medical needs, particularly in oncology, hematology, severe infectious diseases, and rare genetic disorders. Grupo Biotoscana is recognized for its expertise in complex therapeutic areas and maintains long-term collaborations with prominent global pharmaceutical companies, enhancing its ability to deliver specialized treatments and innovative solutions in the healthcare sector.
Synergy CHC
Post in 2017
Synergy CHC Corp. is a consumer health care and beauty company based in Westbrook, Maine, focused on marketing and distributing a diverse range of branded products primarily in the health and wellness sector in North America. The company's portfolio includes FOCUSfactor, a brain-health nutritional supplement; Flat Tummy Tea, a two-step herbal detox product; Hand MD, an anti-aging skincare line; Neuragen, a topical pain relief solution; Sneaky Vaunt, a backless, strapless bra; and Think Fuel, a nootropic supplement aimed at enhancing brain function. Synergy CHC sells its products through various channels, including direct sales to wholesalers and distributors, as well as online platforms and retail outlets. The company aims to grow its portfolio both organically and through acquisitions, having rebranded from Synergy Strips Corp. in 2015.
INTEGA Skin Sciences
Debt Financing in 2016
INTEGA Skin Sciences is a dermatology company that specializes in the development, manufacturing, and marketing of science-based skin care products. It produces and distributes a range of dermatological creams and lotions primarily in Canada and the United States. The company's focus is on delivering quality solutions for skin care, leveraging scientific research to inform its product offerings.
Advaxis
Post in 2015
Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, focused on developing innovative immunotherapies for cancer and infectious diseases. The company's therapies utilize a novel platform based on bio-engineered, live attenuated bacteria that secrete antigen/adjuvant fusion proteins to harness the immune system's response against cancer. Key products under development include axalimogene filolisbac (AXAL), which is in phase II trials for head and neck cancer, and ADXS-PSA for prostate cancer. Additionally, Advaxis is working on ADXS-NEO, which tailors immunotherapy based on a patient's tumor neoantigens, ADXS-HOT for boosting anti-cancer immunity, and ADXS-HER2, targeting HER2-expressing solid tumors. The company has established collaborations and licensing agreements with several organizations, enhancing its research capabilities and development efforts.
Profound Medical
Venture Round in 2015
Profound Medical Corp. is a medical technology company based in Mississauga, Canada, specializing in the development of innovative, incision-free therapeutic systems for the image-guided ablation of diseased tissue. The company’s flagship product, the TULSA-PRO system, integrates real-time magnetic resonance imaging with robotically driven thermal ultrasound to precisely ablate prostate tissue. Additionally, Profound Medical offers the Sonalleve platform, which is designed for treating uterine fibroids and managing palliative pain associated with bone metastases. By leveraging existing MRI infrastructure, the company aims to provide customizable and non-invasive treatment options that address the unmet needs of patients and clinicians. Profound Medical is committed to enhancing the standard of care through its advanced technologies and has established a co-development agreement with GE Healthcare to broaden access to its TULSA-PRO system.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.